Skip to main content
Medivir logo

Medivir — Investor Relations & Filings

Ticker · MVIR ISIN · SE0020181014 LEI · 549300VWDGUX0WMJ1T79 ST Manufacturing
Open in API
Filings indexed 965 across all filing types
Latest filing 2017-10-26 Interim / Quarterly Rep…
Country SE Sweden
Listing ST MVIR

About Medivir

https://www.medivir.com/

Medivir is a pharmaceutical company specializing in the discovery and clinical development of innovative drugs for cancer. The company focuses on oncology areas with high unmet medical needs, aiming to provide transformative treatments for patients with limited therapeutic options. Its research and development strategy is based on extensive expertise in drug design, particularly targeting enzymes such as proteases and polymerases, and includes the use of a proprietary prodrug platform. Medivir actively pursues collaborations with academic and industrial partners to advance its pipeline from research through to commercialization.

Recent filings

Filing Released Lang Actions
Interim / Quarterly Report 2017
Interim / Quarterly Report Classification · 100% confidence The document is a 'Delårsrapport' (Interim Report) for Medivir AB covering the period January to September 2017. It contains detailed financial summaries, income statements, balance sheet data, and management commentary on R&D projects. It is a comprehensive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). 9M 2017
2017-10-26 Swedish
Interim / Quarterly Report 2017
Interim / Quarterly Report Classification · 100% confidence The document is titled 'INTERIM REPORT JANUARY – SEPTEMBER 2017' and contains detailed financial summaries, including net turnover, EBITDA, earnings per share, and cash flow for the specified period. It also includes management commentary, operational updates, and pipeline status. As it provides comprehensive financial data for a period shorter than a full fiscal year, it is classified as an Interim/Quarterly Report. 9M 2017
2017-10-26 English
Medivir receives FDA Fast Track Designation for MIV-711 for the treatment of OA
Regulatory Filings Classification · 95% confidence The document is a press release announcing that Medivir received Fast Track designation from the FDA for its drug candidate MIV-711 for treating Osteoarthritis (OA). It details the significance of the designation, provides background on the drug, and includes standard corporate boilerplate and contact information. This type of announcement, which communicates a specific regulatory or clinical development milestone, does not fit the definitions for 10-K, IR, ER, or CT. It is a specific regulatory/development update. Since it is not a formal filing like a 10-K or a specific report like an AR or SR, and it is not a management change (MANG) or dividend notice (DIV), it falls best under the general 'Regulatory Filings' (RNS) category as a significant, non-standard regulatory event announcement, or potentially a general 'Capital/Financing Update' (CAP) if the designation was expected to immediately impact financing, but RNS is the most appropriate general regulatory announcement fallback.
2017-10-24 English
FDA beviljar Medivir “fast track”-status för MIV-711 för behandling av artros
Regulatory Filings Classification · 95% confidence The document is a press release from Medivir AB announcing that the FDA granted 'fast track' status to their drug MIV-711 for treating osteoarthritis. It details the significance of this status, references previous study results, and includes standard corporate boilerplate and contact information. The text explicitly states, 'Denna information är sådan som Medivir AB är skyldigt att offentliggöra enligt EU:s marknadsmissbruksförordning' (This information is information that Medivir AB is obliged to make public according to the EU's Market Abuse Regulation). This structure—a brief, time-sensitive announcement of a material event, often related to regulatory or corporate news, published under MAR obligations—is characteristic of a general regulatory announcement that doesn't fit the specific financial report categories (like 10-K, ER, IR) or specific corporate actions (like DIV, SHA, DIRS). Therefore, the most appropriate classification is Regulatory Filings (RNS), which serves as the general category for such mandatory disclosures.
2017-10-24 Swedish
Remetinostat phase II data demonstrate efficacy on skin lesions, reduction of itching and high tolerability in patients with early-stage MF-type CTCL
Regulatory Filings Classification · 95% confidence The document is a press release from Medivir AB announcing positive Phase II clinical trial data for their drug remetinostat in treating CTCL. It details efficacy results, safety profiles, and next steps (meeting with regulatory authorities to discuss pivotal trial design). This type of announcement, focusing on clinical trial results and immediate business/regulatory plans, is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is a specific announcement of clinical data and not a comprehensive financial report (10-K, IR) or a general regulatory filing fallback, and it contains key results, it fits best as an Earnings Release (ER) which often includes significant operational updates alongside financial context, or potentially an Investor Presentation (IP) if it were structured as slides, but here it reads like a formal news release. However, looking closely at the definitions, 'ER' is for initial announcement of periodical financial results (quarterly/periodical). This is a clinical trial result announcement. 'RNS' is the general regulatory announcement fallback. Given the content is a major operational/clinical update, and it is not a standard financial report, 'RNS' (Regulatory Filings) is the most appropriate general category for non-standard, material announcements that aren't explicitly covered by other codes like DIV, CAP, or ER (which usually implies earnings figures). The document concludes by stating Medivir is obliged to make this information public pursuant to the EU Market Abuse Regulation, strongly suggesting a mandatory regulatory disclosure, which aligns with RNS.
2017-10-13 English
Fas II-resultat med remetinostat påvisar effekt vid behandling av hudlesioner och klåda, samt uppvisar god tolerabilitet hos patienter med MF/CTCL
Regulatory Filings Classification · 95% confidence The document is a press release from Medivir AB announcing positive Phase II trial results for their drug remetinostat in treating MF/CTCL. It details efficacy data (response rates, pruritus relief) and safety profiles, mentions the results will be presented at an EORTC conference, and concludes with plans to initiate discussions for a pivotal clinical program. The text explicitly states: "Denna information är sådan som Medivir AB är skyldigt att offentliggöra enligt EU:s marknadsmissbruksförordning." This structure—announcing key clinical data and regulatory intent via a press release—is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is a detailed announcement of specific results rather than just a summary of quarterly financials (ER) or a generic filing, and it relates to clinical development progress, it fits best as a general announcement of material information. Given the options, 'Regulatory Filings' (RNS) is the most appropriate fallback for a detailed, non-standard financial/periodic report announcement, although 'ER' might sometimes cover clinical updates if they are tied to a reporting period. However, since this is a specific clinical trial update announcement, RNS is the best fit as it covers general regulatory announcements not covered by other specific codes like 10-K, IR, or ER (which usually focuses on revenue/profit). It is not a transcript (CT), a presentation (IP), or a formal report (AR/IR).
2017-10-13 Swedish

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.